Atossa Therapeutics, Inc. - Common Stock (NQ:ATOS)

2.450 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atossa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

March 19, 2026

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split ↗

February 02, 2026

Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a.m. Eastern Time on February 2,...

Via Stocktwits

Get insights into the top gainers and losers of Friday's after-hours session. ↗

January 16, 2026

Via Chartmill

Atossa Therapeutics Stock Jumps After FDA Grants Rare Pediatric Status To DMD Drug — Retail Bets On Phase 3 Fast-Track ↗

December 11, 2025

Via Stocktwits

MicroMarvel - Atossa Therapeutics ↗

April 06, 2024

Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals

Via Talk Markets

Why Did ATOS Stock Jump 10% In Pre-Market Today? ↗

January 16, 2026

The U.S. Food and Drug Administration granted Orphan Drug Designation to its (Z)-Endoxifen therapy for DMD.

Via Stocktwits

Why Are Shares Of Atossa Therapeutics Up Today? ↗

December 11, 2025

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

December 11, 2025

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

August 29, 2025

Via ACCESS Newswire

Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

August 01, 2025

Via ACCESS Newswire

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

June 05, 2025

Via Benzinga

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 20, 2025

Via ACCESS Newswire

Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 02, 2025

Via ACCESS Newswire

Earnings Scheduled For March 25, 2025 ↗

March 25, 2025

Via Benzinga

Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 11, 2024

Via Benzinga

ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q2 2024 ↗

August 12, 2024

ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗

July 11, 2024

These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.

Via InvestorPlace

3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 ↗

July 03, 2024

If you understand the risks of penny stocks with upside, you may want to investigate these three stocks today.

Via InvestorPlace

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗

June 07, 2024

These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.

Via InvestorPlace

3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off ↗

May 20, 2024

With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation.

Via InvestorPlace

Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 ↗

May 17, 2024

With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.

Via InvestorPlace

ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024 ↗

May 13, 2024

ATOS stock results show that Atossa Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar ↗

May 09, 2024

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider.

Via InvestorPlace

ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 ↗

April 01, 2024

ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market ↗

January 16, 2024

In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.

Via InvestorPlace

This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm" ↗

October 24, 2023

Dr. Steven Quay MD, PhD, President & CEO of Atossa Therapeutics Inc. (NASDAQ: ATOS) was recently interviewed by Benzinga.

Via Benzinga

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment

September 18, 2023

Via ACCESSWIRE

Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment ↗

September 15, 2023

One in eight women will be diagnosed with breast cancer during

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 08, 2023

Via Benzinga

Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst ↗

September 08, 2023

Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.